Magmatic and metamorphic evolution of zircons from the Barro Alto Complex (GO), using backscattered electrons and chemical analyses by electron microprobe.

O zirc?o ? muito utilizado em geocronologia U-Pb por ser considerado um sistema isot?pico fechado e apresentar quantidades elevadas de U e Th. No presente trabalho, foram feitos estudos de imagens de el?trons retroespalhados (BSE) e perfis de varredura espacial por espectr?metro dispersivo em comprimento de onda dos elementos Hf, Y e U em cristais de zirc?o de algumas amostras do Complexo Barro Alto (GO). As imagens de BSE e os perfis evidenciam varia??es nas estruturas internas e na composi??o dos cristais de zirc?o, que s?o reflexos de processos magm?ticos e metam?rf?cos sofridos pela rocha hospedeira. Al?m das fei??es magm?ticas presentes, observamos que os processos metam?rficos encontram-se registrados de forma vari?vel nos cristais de zirc?o, sendo que alguns cristais s?o menos afetados que outros, indicando serem mais resistentes. Em todos os cristais observados, o metamorfismo regional de m?dio a alto grau do Ciclo Brasiliano encontra-se registrado de uma forma mais ou menos intensa, evidenciando a abertura do sistema neste per?odo, que afetou consequentemente o sistema isot?pico.Zircon is a mineral much used in U-Pb geochronology because it is considered a closed system and has fairly high quantities of U and Th. In this paper, we study Barro Alto Complex (Goi?s, Brazil) zircons by backscattered electrons (BSE) imaging and spatial scanning profiles by waveleng dispersive spectrometer of Hf, Y and U. The BSE images and the profiles show variations in the internai structures and composition of zircon crystals that reflect the magmatic and metamorphic processes in the host rocks. Magmatic features are still observed, but metamorphic processes are registered in different textures on the zircons crystals; some are less affected because they are more resistant. The medium to high grade regional metamorphism of the Brasiliano Cycle is registered in ali studied crystals and it may indicate an open-system geochemistry, that consequently affected the U-Pb isotopic system

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib (durvalumab + olaparib arm). The primary end points were progression-free survival (PFS) in the durvalumab arm versus control and the durvalumab + olaparib arm versus control. RESULTS Seven hundred eighteen patients were randomly assigned. In the intention-to-treat population, statistically significant PFS benefit was observed in the durvalumab (hazard ratio [HR], 0.71 [95% CI, 0.57 to 0.89]; P = .003) and durvalumab + olaparib arms (HR, 0.55 [95% CI, 0.43 to 0.69]; P < .0001) versus control. Prespecified, exploratory subgroup analyses showed PFS benefit in dMMR (HR [durvalumab v control], 0.42 [95% CI, 0.22 to 0.80]; HR [durvalumab + olaparib v control], 0.41 [95% CI, 0.21 to 0.75]) and pMMR subgroups (HR [durvalumab v control], 0.77 [95% CI, 0.60 to 0.97]; HR [durvalumab + olaparib v control] 0.57; [95% CI, 0.44 to 0.73]); and in PD-L1-positive subgroups (HR [durvalumab v control], 0.63 [95% CI, 0.48 to 0.83]; HR [durvalumab + olaparib v control], 0.42 [95% CI, 0.31 to 0.57]). Interim overall survival results (maturity approximately 28%) were supportive of the primary outcomes (durvalumab v control: HR, 0.77 [95% CI, 0.56 to 1.07]; P = .120; durvalumab + olaparib v control: HR, 0.59 [95% CI, 0.42 to 0.83]; P = .003). The safety profiles of the experimental arms were generally consistent with individual agents. CONCLUSION Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer

Operacionalização e caracterização de um sistema de análise termogravimétrica para a investigação de mudança de fases induzida termicamente em resinas

16

Caracterização de minerais e texturas do meteorito Vaca Muerta

02